MX2020009278A - Ensayos para detectar la neurodegeneración. - Google Patents

Ensayos para detectar la neurodegeneración.

Info

Publication number
MX2020009278A
MX2020009278A MX2020009278A MX2020009278A MX2020009278A MX 2020009278 A MX2020009278 A MX 2020009278A MX 2020009278 A MX2020009278 A MX 2020009278A MX 2020009278 A MX2020009278 A MX 2020009278A MX 2020009278 A MX2020009278 A MX 2020009278A
Authority
MX
Mexico
Prior art keywords
methods
assays
antibodies
neurodegeneration
detect
Prior art date
Application number
MX2020009278A
Other languages
English (en)
Inventor
Hartmuth Christian Kolb
Gallen Triana-Baltzer
John Randall Slemmon
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2020009278A publication Critical patent/MX2020009278A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/40—Concentrating samples
    • G01N1/4005—Concentrating samples by transferring a selected component through a membrane
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N2030/022—Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027—Liquid chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/14—Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2828—Prion diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography

Abstract

Se proporcionan métodos para medir la cantidad de proteína tau p217+ individual o grupalmente fosforilada en una muestra; además, se proporcionan métodos para detectar o diagnosticar tauopatías, métodos para determinar la eficacia de un tratamiento de una tauopatía, y métodos para determinar si un sujeto es adecuado para la terapia con anticuerpo anti-tau p217+. También se describen anticuerpos para usar en los métodos y kits que comprenden los anticuerpos.
MX2020009278A 2018-03-05 2019-03-04 Ensayos para detectar la neurodegeneración. MX2020009278A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862638524P 2018-03-05 2018-03-05
PCT/IB2019/051747 WO2019171258A1 (en) 2018-03-05 2019-03-04 Assays to detect neurodegeneration

Publications (1)

Publication Number Publication Date
MX2020009278A true MX2020009278A (es) 2021-01-08

Family

ID=67768541

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020009278A MX2020009278A (es) 2018-03-05 2019-03-04 Ensayos para detectar la neurodegeneración.

Country Status (16)

Country Link
US (3) US10591492B2 (es)
EP (1) EP3762414A4 (es)
JP (2) JP7399096B2 (es)
KR (1) KR20200130354A (es)
CN (1) CN112105640A (es)
AU (1) AU2019232630A1 (es)
BR (1) BR112020018193A2 (es)
CA (1) CA3093198A1 (es)
EA (1) EA202092087A1 (es)
IL (1) IL277077A (es)
JO (1) JOP20200216A1 (es)
MA (1) MA53338A (es)
MX (1) MX2020009278A (es)
PH (1) PH12020551371A1 (es)
SG (1) SG11202008574VA (es)
WO (1) WO2019171258A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4040153A4 (en) * 2019-09-30 2023-07-26 Nipro Corporation PROCEDURE FOR DETECTING TAU PROTEIN USING A BLOOD SAMPLE AS SAMPLE
JP2023533806A (ja) * 2020-07-14 2023-08-04 ヤンセン ファーマシューティカ エヌ．ベー． タウオパチー又はアミロイド形成疾患を検出するための血液ベースのアッセイ
US20220127345A1 (en) * 2020-10-26 2022-04-28 Janssen Pharmaceutica Nv Methods of Reducing Tau in Human Subjects
BR112023014151A2 (pt) * 2021-02-19 2023-10-10 Eisai R&D Man Co Ltd Anticorpo tau anti-pt217
CA3233533A1 (en) * 2021-10-01 2023-04-06 Todd Flower Methods and devices for detecting cerebrospinal fluid leakage
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
CN114778856B (zh) * 2022-05-30 2023-03-17 苏州宇测生物科技有限公司 磷酸化tau蛋白检测试剂盒
JP7450995B1 (ja) 2023-04-13 2024-03-18 国立研究開発法人量子科学技術研究開発機構 被験者の脳のタウタンパク質の蓄積量を推定する方法及び装置

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0600951A4 (en) 1991-08-01 1996-10-30 Paul H Voorheis Diagnostic method for alzheimer's disease.
EP0737208B1 (en) 1993-12-21 2006-08-02 Innogenetics N.V. Monoclonal antibodies specific for phf-tau, hybridomas secreting them, antigen recognition by these antibodies and their applications
JPH10506381A (ja) 1994-07-29 1998-06-23 イノジェネティックス・ナムローゼ・フェンノートシャップ 特定のサブクラスまたは形態のホスホリレーションされたｔａｕのエピトープに特異的なモノクローナル抗体、それらを分泌するハイブリドーマ、これらの抗体の抗原認識およびそれらの応用
EP1200073B1 (en) 1999-07-06 2007-01-10 Eli Lilly And Company SELECTIVE iGluR 5? RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE
DE60141752D1 (de) 2000-06-30 2010-05-20 Innogenetics Nv Differentielle diagnose von neurologischen krankheiten
US20030162230A1 (en) 2000-09-27 2003-08-28 Reagan Kevin J. Method for quantifying phosphokinase activity on proteins
JP4393382B2 (ja) 2002-08-14 2010-01-06 三菱化学株式会社 中枢性タウ蛋白質特異的抗体
CA2765099A1 (en) 2009-06-10 2010-12-16 New York University Phosphorylated tau peptide for use in the treatment of tauopathy
JP6124591B2 (ja) 2009-08-28 2017-05-10 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム タウオリゴマーに結合する抗体
GB201111361D0 (en) 2011-07-04 2011-08-17 Nordic Bioscience As Biochemical markers for neurodegenerative conditions
GB201112056D0 (en) * 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
MY186066A (en) * 2011-12-20 2021-06-18 Janssen Biotech Inc Anti-phf-tau antibodies and their uses
WO2014011972A1 (en) 2012-07-13 2014-01-16 Bristol-Myers Squibb Company Tau immunoassay
PT2935326T (pt) * 2012-12-21 2020-09-14 Biogen Ma Inc Anticorpos anti-tau humanos
JP2017512751A (ja) 2014-02-14 2017-05-25 アイピエリアン，インコーポレイティド タウペプチド、抗タウ抗体、およびそれらの使用方法
EP3486256A3 (en) * 2014-06-26 2019-08-28 Janssen Vaccines & Prevention B.V. Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
TWI790642B (zh) * 2015-06-05 2023-01-21 美商建南德克公司 抗-tau抗體及使用方法
US20180186855A1 (en) * 2016-03-23 2018-07-05 Alector Llc Chimeric receptors and methods of use thereof
PE20190208A1 (es) 2016-05-02 2019-02-07 Prothena Biosciences Ltd Anticuerpos que reconocen tau

Also Published As

Publication number Publication date
MA53338A (fr) 2022-01-05
JP2021517239A (ja) 2021-07-15
BR112020018193A2 (pt) 2021-02-02
WO2019171258A1 (en) 2019-09-12
CN112105640A (zh) 2020-12-18
SG11202008574VA (en) 2020-10-29
KR20200130354A (ko) 2020-11-18
US10976325B2 (en) 2021-04-13
EA202092087A1 (ru) 2020-11-17
JP7399096B2 (ja) 2023-12-15
JP2024037794A (ja) 2024-03-19
US20200182888A1 (en) 2020-06-11
US20190271710A1 (en) 2019-09-05
EP3762414A4 (en) 2022-01-05
CA3093198A1 (en) 2019-09-12
AU2019232630A1 (en) 2020-09-24
EP3762414A1 (en) 2021-01-13
PH12020551371A1 (en) 2021-08-23
US20200408781A1 (en) 2020-12-31
JOP20200216A1 (ar) 2020-09-03
IL277077A (en) 2020-10-29
US10591492B2 (en) 2020-03-17

Similar Documents

Publication Publication Date Title
PH12020551371A1 (en) Assays to detect neurodegeneration
SG10201906750XA (en) Assays for detecting the presence or amount of an anti-drug antibody
EA201992748A1 (ru) Диагностические анализы для обнаружения, количественного определения и/или отслеживания микроорганизмов и других аналитов
DE60300339D1 (de) Verfahren zum Nachweis von Karzinomen in solubilisierten zervikalen Körperproben
BRPI0707645B8 (pt) métodos in vitro para detecção de câncer em um indivíduo e para avaliação de prognóstico de um indivíduo tendo, ou suspeito de ter, câncer ovariano
MX2018009738A (es) Anticuerpos monoclonales de proteína ns1 anti-virus del dengue.
BR112015021199A2 (pt) método para determinar se uma infeção é bacteriana e/ou viral, dispositivo de fluxo lateral para detecção de um analito em uma amostra, e, dispositivo para detecção de um marcador bacteriano e/ou viral em uma amostra
WO2009092386A3 (en) A new method to measure and characterize microvesicles in the human body fluids
BR112014006741A2 (pt) método para monitorização, diagnóstico e/ou prognóstico de lesão renal aguda no estágio inicial
DE60129151D1 (de) Verfahren zur erkennung von eierstockkrebs mittels menschlichem kallikrein (hk6)
BRPI0923199B8 (pt) método para determinar a presença de anticorpos de fixação de complemento
BR112016007037A2 (pt) método para detectar câncer pancreático, anticorpo monoclonal e kit
MX2019006098A (es) Ensayo de anticuerpos.
FR2894675B1 (fr) Distinction des meningites bacteriennes et virales
WO2012021741A3 (en) Lateral flow assays for non-diagnostic analytes
WO2018172337A8 (en) IMMUNOASSAY FOR THE DETECTION OF ZIKA VIRUS INFECTION
WO2014126487A3 (en) Diagnosis and detection of dengue virus infection using chicken egg antibodies
MX2023007633A (es) Inmunoensayo diva de la fiebre porcina africana.
DE602004026869D1 (de) Diagnose von leberzirrhose mittels eines für menschliches protoonkogenes protein spezifischen antikörpers
NO20016080D0 (no) Analyse
FR2874093B1 (fr) Methode et trousse de determination du statut vaccinal de personnes
MX2017017100A (es) Uso de la combinación de biomarcadores y anticuerpos séricos para el diagnóstico de tuberculosis humana.
Makiguchi et al. A56 (PATHO)-PHYSIOLOGY OF THE ALVEOLUS: The Detection Of Cell Type-Specific Extracellular Vesicles Derived From Lung Epithelial Cells, Stable Or Cytokine-Activated Endothelial Cells By Exoscreen
GB0501564D0 (en) Test for prion disease
UA131868U (uk) Комплект для експрес-діагностики інфекційних захворювань